Core Viewpoint - The announcement by Ruizhi Pharmaceutical Technology Co., Ltd. regarding the establishment of an industrial investment fund with a total subscription amount of 200 million RMB, primarily targeting the healthcare industry and focusing on innovative drugs [1][3]. Group 1: Fund Establishment Details - The fund will be established in partnership with Shenzhen Investment Holdings Donghai Investment Co., Ltd. and other limited partners, with a total subscription amount of 200 million RMB [1][3]. - The fund's name is Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industrial Partnership (Limited Partnership), with Ruizhi's subsidiary contributing 58 million RMB, accounting for 29% of the total subscription [3][5]. - The Luohu District-level mother fund will contribute 140 million RMB, representing 70% of the total subscription [3][4]. Group 2: Fund Management and Investment Focus - The fund will focus on equity investments in the healthcare industry, particularly in innovative drugs and medical devices [5][6]. - Shenzhen Investment Holdings Donghai will act as the general partner and fund manager, with a focus on industrial technology, digital intelligence, and life health sectors [5][6]. Group 3: Fund Terms and Conditions - The fund has a duration of 7 years, with a 4-year investment period followed by a 3-year exit period, and can be extended by 2 years with unanimous agreement [6]. - Management fees will be charged at 2% during the investment period and 1.5% during the exit period, with no fees during the extension period [6]. - Strict reinvestment requirements include relocating the headquarters of invested companies to Luohu or establishing subsidiaries there, ensuring that revenues remain in the district [6][7].